Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

被引：0

作者：

Mathew Vithayathil

Antonio D’Alessio

Claudia Angela Maria Fulgenzi

Naoshi Nishida

Martin Schönlein

Johann von Felden

Kornelius Schulze

Henning Wege

Anwaar Saeed

Brooke Wietharn

Hannah Hildebrand

Linda Wu

Celina Ang

Thomas U. Marron

Arndt Weinmann

Peter R. Galle

Dominik Bettinger

Bertram Bengsch

Arndt Vogel

Lorenz Balcar

Bernhard Scheiner

Pei-Chang Lee

Yi-Hsiang Huang

Suneetha Amara

Mahvish Muzaffar

Abdul Rafeh Naqash

Antonella Cammarota

Valentina Zanuso

Tiziana Pressiani

Matthias Pinter

Alessio Cortellini

Masatoshi Kudo

Lorenza Rimassa

David J. Pinato

Rohini Sharma

机构：

[1] Imperial College London,Department of Surgery & Cancer

[2] Hammersmith Campus,Department of Biomedical Sciences

[3] Humanitas University,Division of Medical Oncology

[4] Policlinico Universitario Campus Bio-Medico,Department of Gastroenterology and Hepatology, Faculty of Medicine

[5] Kindai University,Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology

[6] University Medical Center Hamburg-Eppendorf,Department of Gastroenterology and Hepatology

[7] University Medical Center Hamburg-Eppendorf,Division of Medical Oncology, Department of Medicine

[8] Kansas University Cancer Center,Division of Hematology/Oncology, Department of Medicine

[9] Tisch Cancer Institute,I. Medical Department

[10] Mount Sinai Hospital,Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine

[11] University Medical Center Mainz,Division of Gastroenterology & Hepatology, Department of Internal Medicine III

[12] Freiburg University Medical Center,Division of Gastroenterology and Hepatology, Department of Medicine

[13] University of Freiburg,Institute of Clinical Medicine, School of Medicine

[14] University of Freiburg,Division of Hematology/Oncology

[15] Signalling Research Centers BIOSS and CIBSS,Medical Oncology and Hematology Unit

[16] German Cancer Consortium (DKTK),Division of Oncology, Department of Translational Medicine

[17] Hannover Medical School,undefined

[18] Medical University of Vienna,undefined

[19] Taipei Veterans General Hospital,undefined

[20] National Yang Ming Chiao Tung University,undefined

[21] East Carolina University,undefined

[22] Medical Oncology/TSET Phase 1 Program,undefined

[23] Stephenson Cancer Center,undefined

[24] University of Oklahoma,undefined

[25] Humanitas Cancer Center,undefined

[26] IRCCS Humanitas Research Hospital,undefined

[27] University of Piemonte Orientale,undefined

来源：

Hepatology International | 2023年 / 17卷

关键词：

Immunotherapy; Anti-programmed death-ligand; Anti-vascular endothelial growth factor; Checkpoint inhibitor; Obesity; Cirrhosis; Overall survival; Progression-free survival; Overweight; Non-alcoholic fatty liver disease;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：904 / 914

页数：10

共 50 条

[41] Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
Manzar, Gohar Shahwar
De, Brian Sandeep
Abana, Chike Osita
Lee, Sunyoung S.
Javle, Milind
Kaseb, Ahmed O.
Vauthey, Jean-Nicolas
Cao, Hop Sanderson Tran
Koong, Albert C.
Li Smith, Grace
Taniguchi, Cullen M.
Holliday, Emma Brey
Das, Prajnan
Koay, Eugene Jon
Ludmir, Ethan Bernard
CANCERS, 2022, 14 (08)
[42] Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
Brackenier, Cedric
Kinget, Lisa
Cappuyns, Sarah
Verslype, Chris
Beuselinck, Benoit
Dekervel, Jeroen
CANCERS, 2023, 15 (02)
[43] Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
Satake, Tomoyuki
Shibuki, Taro
Watanabe, Kazuo
Sasaki, Mitsuhito
Imaoka, Hiroshi
Mitsunaga, Shuichi
Kojima, Motohiro
Ikeda, Masafumi
FRONTIERS IN ONCOLOGY, 2023, 13
[44] Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
Kim, Ji Hoon
Nam, Hee-Chul
Kim, Chang-Wook
Cho, Hee Sun
Yoo, Jae-Sung
Han, Ji Won
Jang, Jeong Won
Choi, Jong Young
Yoon, Seung Kew
Yang, Hyun
Bae, Si Hyun
Kim, Suho
Oh, Jung Suk
Chun, Ho Jong
Jeon, Chang Ho
Ahn, Jaegyoon
Sung, Pil Soo
CANCERS, 2023, 15 (17)
[45] Impact of body mass index on survival of esophageal squamous carcinoma patients in southern China
Ren, Chao
Cai, Xiu-Yu
Qiu, Miao-Zhen
Wang, De-Shen
Wang, Feng-Hua
Luo, Hui-Yan
Xu, Rui-Hua
JOURNAL OF THORACIC DISEASE, 2015, 7 (03) : 337 - 345
[46] A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
Lee, Soon Kyu
Kwon, Jung Hyun
Lee, Sung Won
Lee, Hae Lim
Kim, Hee Yeon
Kim, Chang Wook
Song, Do Seon
Chang, U. Im
Yang, Jin Mo
Nam, Soon Woo
Kim, Seok-Hwan
Song, Myeong Jun
Kim, Ji Hoon
Lee, Ahlim
Yang, Hyun
Bae, Si Hyun
Han, Ji Won
Nam, Heechul
Sung, Pil Soo
Jang, Jeong Won
Choi, Jong Young
Yoon, Seung Kew
Shim, Dong Jae
Kim, Doyoung
Kim, Myungsoo
CANCERS, 2023, 15 (17)
[47] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
Sae Yumita
Sadahisa Ogasawara
Miyuki Nakagawa
Susumu Maruta
Tomomi Okubo
Norio Itokawa
Yotaro Iino
Masamichi Obu
Yuki Haga
Atsuyoshi Seki
Tadayoshi Kogure
Takamasa Ishino
Keita Ogawa
Kisako Fujiwara
Terunao Iwanaga
Naoto Fujita
Takafumi Sakuma
Ryuta Kojima
Hiroaki Kanzaki
Keisuke Koroki
Masanori Inoue
Kazufumi Kobayashi
Soichiro Kiyono
Masato Nakamura
Naoya Kanogawa
Tomoko Saito
Takayuki Kondo
Ryo Nakagawa
Shingo Nakamoto
Ryosuke Muroyama
Tetsuhiro Chiba
Ei Itobayashi
Masanori Atsukawa
Yoshihiro Koma
Ryosaku Azemoto
Kenji Ito
Hideaki Mizumoto
Jun Kato
Naoya Kato
BMC Gastroenterology, 23
[48] Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Qin, Shukui
Ren, Zhenggang
Feng, Yin-Hsun
Yau, Thomas
Wang, Baocheng
Zhao, Haitao
Bai, Yuxian
Gu, Shanzhi
Li, Lindong
Hernandez, Sairy
Xu, Derek-Zhen
Mulla, Sohail
Wang, Yifan
Shao, Hui
Cheng, Ann Lii
LIVER CANCER, 2021, 10 (04) : 296 - 308
[49] Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report
Kumar, Pramod
Krishna, Pradeep
Nidoni, Ravindra
Adarsh, C. K.
Arun, M. G.
Shetty, Aashish
Mathangi, J.
Sandhya
Gopasetty, Mahesh
Venugopal, B.
AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (06) : 1087 - 1090
[50] The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma
Mukozu, Takanori
Nagai, Hidenari
Nagumo, Hideki
Mohri, Kunihide
Yoshimine, Naoyuki
Kobayashi, Kojiro
Ogino, Yu
Matsui, Teppei
Daido, Yasuko
Wakui, Noritaka
Momiyama, Koichi
Higai, Koji
Matsuda, Takahisa
Igarashi, Yoshinori
ONCOLOGY, 2025, 103 (04) : 277 - 289

← 1 2 3 4 5 →